Loading data for DMRA — first visit, this takes a few seconds.
Damora Therapeutics, Inc. (DMRA)
NasdaqCM: DMRA
· 即時價格 · USD
29.00
-1.60 (-5.23%)
收盤價： Sep 02, 2026, 8:00 PM
股價、關鍵數字和最新消息，都在這一頁。
Damora Therapeutics, Inc.（DMRA）股價、分析與資料
無可用資料
| 買價 | 21.68 |
| 市值 | 1.74B |
| 營收 (ttm) | n/a |
| 淨利（ttm） | -241M |
| 1.48 | |
| -0.26 | |
| n/a | |
| -13.15 | |
| P/B (ttm) | 4.51 |
| P/S (ttm) | 0.00 |
| 財報日期 | Nov 5, 2026 |
| 賣價 | 36.68 |
| 成交量 | 371,723 |
| 20 日平均成交量 | 565,965 |
| 開盤價 | 30.38 |
| 前收盤價 | 30.60 |
| 當日區間 | 28.41 - 30.71 |
| 52 週範圍 | 2.45 - 38.33 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 DMRA
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN ...
完整的公司簡介財報驚奇
Damora Therapeutics 已於 Aug 10, 2026 公布季度財報：
- 營收為 $0 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 -0.39 低於預期 -0.02, 年增 92.20% 成長.
第 1 頁，共 2 頁